Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study

被引：0
|
作者：
Shiori Hishida-Sadaka
Hirotoshi Iihara
Koichi Ohata
Serika Matsuoka
Daichi Watanabe
Takuji Iwashita
Shinya Uemura
Masahito Shimizu
Akio Suzuki
机构：
[1] Gifu University Hospital,Department of Pharmacy
[2] Gifu University Hospital,Patient Safety Division
[3] Gifu Pharmaceutical University,Laboratory of Pharmacy Practice and Social Science
[4] Gifu University Graduate School of Medicine,Department of Gastroenterology
[5] Gifu Pharmaceutical University,Laboratory of Advanced Medical Pharmacy
来源：
Supportive Care in Cancer | 2023年 / 31卷
关键词：
Advanced pancreatic cancer; Antiemetic therapy; Chemotherapy; Chemotherapy-induced nausea and vomiting;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 45 条
  • [31] PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF SUSTAINED-RELEASE GRANISETRON (APF530) AND PALONOSETRON IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN CANCER PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY
    Smith, Carrie
    Gabrail, Nashat
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E97 - E97
  • [32] Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study
    Iihara, Hirotoshi
    Shimokawa, Mototsugu
    Hayasaki, Yoh
    Fujita, Yukiyoshi
    Abe, Masakazu
    Takenaka, Motoki
    Yamamoto, Senri
    Arai, Takahiro
    Sakurai, Michiru
    Mod, Minako
    Nakamura, Kazuto
    Kado, Nobuhiro
    Murase, Saki
    Shimaoka, Ryuichi
    Suzuki, Akio
    Morishige, Ken-ichirou
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 629 - 635
  • [33] Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
    P. J. Hesketh
    S. M. Grunberg
    J. Herrstedt
    R. de Wit
    R. J. Gralla
    A. D. Carides
    A. Taylor
    J. K. Evans
    K. J. Horgan
    Supportive Care in Cancer, 2006, 14
  • [34] Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting:: effect of gender on treatment response
    Hesketh, PJ
    Grunberg, SM
    Herrstedt, J
    de Wit, R
    Gralla, RJ
    Carides, AD
    Taylor, A
    Evans, JK
    Horgan, KJ
    SUPPORTIVE CARE IN CANCER, 2006, 14 (04) : 354 - 360
  • [35] A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin's lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists
    Takahashi, Tsutomu
    Kumanomidou, Satoshi
    Takami, Saki
    Okada, Takahiro
    Adachi, Koji
    Jo, Yumi
    Ikejiri, Fumiyoshi
    Onishi, Chie
    Kawakami, Koshi
    Miyake, Takaaki
    Inoue, Masaya
    Moriyama, Ichiro
    Suzuki, Ritsuro
    Suzumiya, Junji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (03) : 378 - 383
  • [36] A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin’s lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists
    Tsutomu Takahashi
    Satoshi Kumanomidou
    Saki Takami
    Takahiro Okada
    Koji Adachi
    Yumi Jo
    Fumiyoshi Ikejiri
    Chie Onishi
    Koshi Kawakami
    Takaaki Miyake
    Masaya Inoue
    Ichiro Moriyama
    Ritsuro Suzuki
    Junji Suzumiya
    International Journal of Hematology, 2016, 104 : 378 - 383
  • [37] Retrospective Analysis of Palonosetron Compared with Older 5-HT3 Receptor Antagonists (Ondansetron, Dolasetron, and Granisetron) in Preventing Anthracycline-Induced Nausea and Vomiting in Breast Cancer Patients from Four Phase 3 Trials.
    Rugo, H. S.
    Schwartzberg, L.
    Morrow, G. R.
    Barbour, S. Y.
    Ballinari, G.
    Thorn, M. D.
    Cox, D.
    CANCER RESEARCH, 2011, 71
  • [38] TRIAL IN PROGRESS: A MULTICENTER PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF DENOSUMAB IN GASTROINTESTINAL CANCER PATIENTS RECEIVING SHORT-TERM PERIODIC STEROID PREMEDICATION FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (ESPRESSO-02)
    Muranaka, T.
    Nakamura, M.
    Yagisawa, M.
    Kobayashi, Y.
    Harada, K.
    Sogabe, S.
    Dazai, M.
    Okamura, O.
    Yuki, S.
    Ishiguro, A.
    Tsuji, Y.
    Ono, K.
    Sakamoto, N.
    Komatsu, Y.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S354 - S355
  • [39] A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting: ESPRESSO-02/HGCSG1602.
    Nakamura, Michio
    Yagisawa, Masataka
    Sawada, Kentaro
    Muranaka, Tetsuhito
    Nakatsumi, Hiroshi
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Dazai, Masayoshi
    Ishiguro, Atsushi
    Kobayashi, Yoshimitsu
    Sogabe, Susumu
    Miyagishima, Takuto
    Iwanaga, Ichiro
    Tateyama, Miki
    Hatanaka, Kazuteru
    Ono, Kota
    Sakata, Yuh
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [40] Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial
    Grunberg, Steven M.
    Rolski, Janusz
    Strausz, Janos
    Aziz, Zeba
    Lane, Stephen
    Russo, Mark W.
    Wissel, Paul
    Guckert, Mary
    Wright, Oliver
    Herrstedt, Jorn
    LANCET ONCOLOGY, 2009, 10 (06): : 549 - 558
12345